Gregory Vidal: How TDXd Has impacted How We Treat Early Her2 Positive Breast Cancer?
Gregory Vidal, Director of Clinical Research at West Cancer Center & Research Institute, shared a post on LinkedIn: “I led a great discussion with Dr. Pooja Advani of Mayo Jacksonville […]
Read the full articleYou might also wanna read
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
Conditions : Advanced Breast Cancer; Metastatic Breast Cancer; HER2 Positive; HR Positive Interventions : Drug: Trastuzumab deruxtecan; Drug
Later-Line Treatments for HER2-Positive Breast Cancer
(MedPage Today) -- Based on results from the DESTINY-Breast03 trial, trastuzumab deruxtecan (T-DXd; Enhertu) became the preferred, guideline
De-Escalation, Genomics and Multidisciplinary Care Redefines Breast Cancer Treatment
Amanda Amin, MD, Janice Lyons, MD and Alberto Montero, MD, explore the evolution of breast cancer treatment. The discussion highlights how p
How breast cancer is detected and treated; suicide prevention efforts; trying to reduce chemotherapy's side effects: Upstate Medical University's HealthLink on Air for Sunday, Feb. 9, 2020
Interviews with Upstate breast surgery chief Ranjna Sharma, MD; psychiatrists Seetha Ramanathan, MD, from Upstate, and Jay Carruthers, MD, f
GE HealthCare and Mayo Clinic launch theranostics study to personalize prostate cancer treatment
CHICAGO, Ill. and ROCHESTER, Minn. — GE HealthCare and Mayo Clinic today announced the MI-BET (Molecular Imaging Biomarker-Based End of Ther
mayocl.in·8d agoResearch on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy
Conditions : Breast Cancer Sponsors : Zhejiang Cancer Hospital Not yet recruiting
Comments
Sign in to join the conversation.
No comments yet. Be the first.